Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient

J Clin Endocrinol Metab. 2001 Feb;86(2):478-81. doi: 10.1210/jcem.86.2.7206.

Abstract

We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during treatment with pegvisomant. The patient described did benefit from cotreatment with pegvisomant and octreotide, including decreased GH levels, normalization of serum insulin-like growth factor I concentrations, and improvement of visual field defects.

Publication types

  • Case Reports

MeSH terms

  • Acromegaly / drug therapy
  • Acromegaly / etiology*
  • Adenoma / complications
  • Adenoma / drug therapy*
  • Adenoma / surgery
  • Adult
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Drug Therapy, Combination
  • Human Growth Hormone / analogs & derivatives*
  • Human Growth Hormone / blood
  • Human Growth Hormone / therapeutic use*
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Neoplasm Recurrence, Local / drug therapy*
  • Octreotide / therapeutic use*
  • Pituitary Neoplasms / complications
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / surgery
  • Receptors, Somatotropin / antagonists & inhibitors

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Somatotropin
  • Human Growth Hormone
  • Insulin-Like Growth Factor I
  • pegvisomant
  • Octreotide